BioXcel Therapeutics Inc Commercial Day Transcript
Thank you for joining the BioXcel Therapeutics Virtual Commercial Day event highlighting BXCL501 as a potential treatment for the acute treatment of agitation associated with schizophrenia and bipolar disorders. (Operator Instructions) At this time, I would like to turn the call over to Vimal Mehta, Chief Executive Officer of BioXcel Therapeutics.
Thank you, operator. Good afternoon, everyone, and thank you for joining our Commercial Day to discuss our launch strategy for BXCL501, which is currently under FDA review for the acute treatment of agitation associated with schizophrenia and bipolar disorder. As a reminder, during today's presentation, we will be making forward-looking statements regarding our commercialization plans. These statements are subject to risks and uncertainties that may cause actual results to materially differ from those forecasts. A description of these risks can be found in our most recent 10-Q on file with the SEC.
Next slide, please. Joining
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |